Abstract 117P
Background
Hepatoid adenocarcinoma of stomach (HAS) is a rare subtype of gastric cancer (GC) with hepatocyte-like differentiation and a dismal prognosis. Although HAS has different histological and molecular properties and more aggressive biological behavior, most patients with HAS still receive the same regimen as usual GC. A comprehensive understanding of the molecular properties of HAS may provide insights into personalized diagnosis and treatment, however, this area is under-studied.
Methods
We aimed to explore methylome and transcriptome profiling of HAS in a relatively precise scenario. The laser capture microdissection (LCM) was used to isolate thirty-two formalin fixed paraffin-embedded (FFPE) tissue into gastric adenocarcinoma section (GAC) and hepatocellular-like section (HAS). According to the manufacturer's protocol, DNA-associated methylation sequencing and RNA-associated transcriptome sequencing were performed.
Results
With Laser-Capture Microdissection (LCM) technique, we separate HAS FFPE sample into gastric adenocarcinoma component (GAC) and HAS component. The whole genome RNAseq and methylation sequencing (GMseq) were used to explore HAS expression patterns and methylation modification profile. We found that differentially methylated cytosine was effective in distinguishing GAC from HAS, and stem cell-related gene expression and pathway enrichment were higher in GAC than in HAS. Correspondingly, HAS showed TNFSF15 gene significantly hypermethylation and lower expression features. In addition, in vivo xenograft models derived from TNFSF15 knockout cells showed higher aggressiveness and hepatocyte-like gene expression. Our study sheds light on the critical role of TNFSF15 in HAS transdifferentiation, and intervening methylation of TNFSF15 may be a clinical option to improve prognosis and reduce metastasis.
Conclusions
In summary, we found that the GAC component has the expression features of pluripotent stem cells and mesothelial cells, and the HAS component has the features of hepatoblast and mature hepatocytes. We propose that GAC mesoderm and endoderm dedifferentiation bias TME as the key role to HAS transdifferentiation and TNFSF15 may be a key regulatory factor in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Tumorspheres cultured from circulating cancer stem cells overexpress the innate checkpoint CD47 in breast cancer patients
Presenter: Monika Pizon
Session: Poster session 08
Resources:
Abstract
164P - A spatially informed transcriptomic model to forecast early resistance to front-line osimertinib in advanced EGFR-mutant NSCLC
Presenter: Jon Zugazagoitia
Session: Poster session 08
165P - Consistency analysis of c-Met protein expression over time in patients with non-squamous non-small cell lung cancer
Presenter: Alexis Cortot
Session: Poster session 08
166P - Integrative multi-omics refine molecular diagnostics in non-small cell lung cancer
Presenter: Li Ren Kong
Session: Poster session 08
167P - Tumor-immune spatial interactions on NSCLC H&E slide images predicts immunotherapy response: Preliminary external validation
Presenter: Liam Il-Young Chung
Session: Poster session 08
168P - Biosimulation coupled with personalized tumor microenvironment (TME) modeling predicts response to immunotherapy treatment in NSCLC patients
Presenter: Himanshu Grover
Session: Poster session 08
169P - Analysis of tumor immune microenvironment with mIHC in Chinese non-small cell lung cancer
Presenter: Hao Wu
Session: Poster session 08
170P - Clinical presentations and prognosis of HER2-low breast cancer in Taiwan
Presenter: Grace Chen
Session: Poster session 08
171P - A computational pathology collagen signature predictive of tamoxifen benefit in ductal carcinoma in situ: Results from a cohort within the UK/ANZ DCIS randomized trial
Presenter: Arpit Aggarwal
Session: Poster session 08
172P - HER2 expression across solid tumors and real-world implications for use of fam-trastuzumab deruxtecan-nxki (T-Dxd)
Presenter: Ahmed Ismail
Session: Poster session 08